TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01221792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non active comparator
Study: NCT02218749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initially triaged to physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initially triaged to physician
Study: NCT02334358

Intervention type: DEVICE
Intervention: YVOIRE Classic s
Study: NCT02178735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior vaginal tailored mesh surgery
Description: Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior vaginal tailored mesh surgery
Description: Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior vaginal tailored mesh surgery
Description: Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
Study: NCT02978664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange
Description: Water will infused and removed during insertion phase of colonoscopy
Study: NCT04278508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
Study: NCT02581982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02178735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior vaginal tailored mesh surgery
Description: Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
Study: NCT02581982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00141557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esterified estrogens 1.25mg and methyltestosterone 2.5mg
Description: ESTRATEST® administered orally QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified estrogens 1.25 mg
Description: Esterified estrogens 1.25 mg administered orally QD
Study: NCT02128802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss Program
Study: NCT04372082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen...) during the whole study duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen...) during the whole study duration
Study: NCT01654939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
Study: NCT03902795

Intervention type: DIAGNOSTIC_TEST
Intervention: Microperimetry
Description: Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.

Intervention type: DIAGNOSTIC_TEST
Intervention: M-charts
Description: The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
Study: NCT05230576

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning training cohort
Description: train the deep learning model

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning validation cohort
Description: evaluate the model
Study: NCT05000307

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
Study: NCT02568722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard RRT initiation
Description: In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation
Description: A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
Study: NCT04285697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infection prevention bundle
Description: The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family
Study: NCT04372082

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (SOC)
Description: SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen...) during the whole study duration
Study: NCT04390399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2', 2'-difluoro 2'deoxycytidine, dFdC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan liposome
Description: Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
Study: NCT04372082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg x 3 per day during 10 days in addition to SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of diltiazem and niclosamide
Description: niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
Study: NCT04100408

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Undergo saliva or buccal mucosa collection

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06357975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study: NCT03444324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT524
Description: BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinical condition.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FFP/Cryo
Description: FFP/Cryo was administered intravenously; dosage according to local standards in mL per kg body weight.
Study: NCT02977078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active feedback on monitored inhaler use
Description: Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler casing
Description: Monitors inhaler use

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler casing
Description: Monitors inhaler use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Mobile application software linked to inhaler casing
Study: NCT04527835

Intervention type: DIAGNOSTIC_TEST
Intervention: ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
Description: ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
Study: NCT01985022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-ESI
Description: The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-ESI
Description: The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
Study: NCT03315728

Intervention type: OTHER
Intervention: Quality Improvement Strategy
Description: Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
Study: NCT01128335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF(1000mg bid) + tacrolimus + standard of care medications
Description: MMF(1000mg bid) + tacrolimus + standard of care medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (200mg bid) + tacrolimus + standard of care medications
Description: sotrastaurin (200mg bid) + tacrolimus + standard of care medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (200mg bid) + tacrolimus + standard of care medications
Description: sotrastaurin (200mg bid) + tacrolimus + standard of care medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Description: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Study: NCT01907841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ischemic Preconditioning
Study: NCT02405806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low carbohydrate food
Description: low carbohydrate food

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard food
Description: standard food
Study: NCT01174953

Intervention type: DRUG
Group type: OTHER
Intervention: finasteride
Description: Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)
Study: NCT03371732

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Intervention group
Description: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational advises group
Description: Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
Study: NCT03165942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcoholic Beverage
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Alcoholic Beverage
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Study: NCT03160664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100 + Option
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study: NCT03529123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous
Study: NCT01985022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual-ESI
Description: The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
Study: NCT01685073

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MET/CBT
Description: a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
Study: NCT03529123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine (HMR1964)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine (HMR1964)
Description: Pharmaceutical form: Injection~Route of administration: Subcutaneous
Study: NCT02496377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous glycine sulfate Tardyferon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Study: NCT01685073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT
Description: a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
Study: NCT03480438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
Study: NCT03979820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenelzine sulfate
Description: Film-coated tablet
Study: NCT01392573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
Study: NCT02330614

Intervention type: OTHER
Intervention: Bleaching by peroxide carbamide 10%
Description: bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
Study: NCT02496377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose Ferinject